Compliance Engineering Protein Production 
The Pharma Data
JUNE 25, 2025
Salanersen was engineered as an advanced ASO therapeutic, building on Biogen’s experience with SPINRAZA. The goal is to boost SMN protein production more effectively and offer a more convenient, once-a-year dosing schedule , thereby improving long-term disease management and patient compliance.
Drug Target Review
APRIL 5, 2024
Together, these attributes provide a strong foundation for protein expression with enough adaptability to produce much of the commercial and therapeutic protein market. Skilled CDMOs can also locate or create favourable genomic microenvironments where transcription factors are efficiently recruited, further boosting protein production.
Drug Target Review
MARCH 15, 2024
Advancements in genetic and protein engineering through technology innovation, automation, and more recently machine learning, have led to the development of more complex molecules such as bispecific antibodies and antibody drug conjugates. References Mistry RK, Kelsall E, Sou SN, et al. Budge JD, Knight TJ, Povey J, et al.
Expert insights. Personalized for you.
Let's personalize your content